Vascular disease

Eyemart Express' Expert Insights on Dry Eyes for Healthy Vision Month

Retrieved on: 
星期一, 五月 6, 2024
Tears, Climate, Health, Vascular disease, Paratriathlon, Blinking, Diet, Eye, Work, Salmon, Diagnosis, Allergy, Vein, Artery

FARMERS BRANCH, Texas, May 6, 2024 /PRNewswire/ -- May is Healthy Vision Month, and Eyemart Express is taking the opportunity to shed light on an often overlooked yet prevalent issue: dry eyes. Approximately 50.2 million Americans suffer from dry eyes, and that number is increasing with our growing dependence on technology and looking screens for work and entertainment all day. The national optical retailer is partnering with Dr. Lavar Kofoed, an experienced eye doctor with practices across Utah and Idaho, to build awareness about dry eyes, including symptoms and easy treatments to keep the eyes healthy.

Key Points: 
  • The national optical retailer is partnering with Dr. Lavar Kofoed , an experienced eye doctor with practices across Utah and Idaho, to build awareness about dry eyes, including symptoms and easy treatments to keep the eyes healthy.
  • Getting a formal diagnosis from an eye doctor is an important first step in treating dry eyes.
  • When it comes to diagnosing and treating dry eyes, Dr. Kofoed recommends starting with an annual eye exam.
  • "It is necessary to support the pillars for wellness to treat and prevent dry eyes outside of an eye doctor's office."

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Retrieved on: 
星期四, 四月 18, 2024
Mortality, University, Fibrosis, University of Leeds, TEL, Systemic scleroderma, Synovitis, Nature, Skin, CMMB, Primary sclerosing cholangitis, Prognosis, Communication, Serum, Vascular disease, Physiology, Doctor of Philosophy, Calcinosis, Rheumatology, History, ILD, IND, PSC, Disease, Therapy, Risk, Patient, CSO, Scleroderma, Lung, Clinical trial, CCL24, Pharmaceutical industry

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced the publication of a new study that further confirms the key role of its novel soluble protein target CCL24 in systemic sclerosis (SSc). The study, “Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis,” was published in the current edition of the journal Arthritis Care and Research.1

Key Points: 
  • It explored the relationship between serum CCL24 levels and SSc severity and prognosis.
  • One in four patients in a real-life SSc population was found to have a high CCL24 serum concentration, despite standard of care treatment with immunosuppressive therapy.
  • The analysis found that higher CCL24 levels were linked to critical clinical variables associated with the most severe forms of SSc.
  • Crucially, high serum CCL24 was predictive of lung deterioration and a higher baseline CCL24 level was associated with higher 10-year SSc-related mortality.

Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems

Retrieved on: 
星期一, 四月 22, 2024
FDA, Physics, Food, Cleveland Clinic, Vascular disease, ICE, Doctor of Philosophy, Moyamoya disease, Patient, Physician, Circulatory system, Expanse, Angiology, Thrombectomy, Growth, Medical device

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.

Key Points: 
  • PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.
  • The ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
  • The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies.
  • "The thrombectomy market is witnessing robust growth and the approval of the ICE system comes at an auspicious time.

Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems

Retrieved on: 
星期一, 四月 22, 2024
Physics, Food, Cleveland Clinic, Vascular disease, ICE, Doctor of Philosophy, Moyamoya disease, Patient, Physician, Circulatory system, Expanse, Angiology, Thrombectomy, Growth

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.

Key Points: 
  • PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.
  • The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies.
  • Eitan Konstantino, PhD, a serial entrepreneur in the vascular device field, is the driving force behind Expanse ICE.
  • "The thrombectomy market is witnessing robust growth and the approval of the ICE system comes at an auspicious time.

NYU Langone Health's New Optimal Aging Institute to Further Explore the Link Between Vascular Health and Aging

Retrieved on: 
星期四, 四月 11, 2024
Kidney disease, Mayo Clinic, Protein, Risk, Blood, Research, Doctor of Philosophy, Cognition, NYU, Life, Lung, Biomarker, Sleep, Population health, Vascular disease, NINDS, NYU Langone Health, University of Texas System, Alzheimer's disease, Baylor College of Medicine, Dementia, University of Minnesota, Ageing, SDOH, Johns Hopkins University, Huber loss, NIH, Amnesia, Publication, Tissue, Heart, MIND, Female, Multimorbidity, Clinical trial, University, Bangladesh Technical Education Board, DSM-IV codes, Notifiable disease, Policy, Frailty, MD, ARIC, Atherosclerosis, Disease, Hypertension, Community, Pharmaceutical industry

NEW YORK, April 11, 2024 /PRNewswire/ -- Researchers at the newly-formed Optimal Aging Institute at NYU Langone Health have been awarded $31 million by the National Institutes of Health (NIH) for a diverse, ten university cohort to study how vascular risk factors contribute to dementia and other age-related disorders in those over the age of 85, building upon existing research.

Key Points: 
  • Close integration with partners across NYU Langone Health system, Coresh said, enables the Institute to implement and test interventions with real-world impacts in real-time, advancing practice-changing research to improve outcomes for all.
  • to highlight an important topic at the intersection of vascular health and aging.
  • The event, co-sponsored by NYU Langone's Department of Population Health and the Optimal Aging Institute, will feature six renowned experts in the field and will showcase recent groundbreaking research on how treating hypertension may prevent dementia.
  • The research is supported by The National Heart, Lung, and Blood Institute, a division of the NIH, grant number U01HL096812.

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Retrieved on: 
星期五, 三月 22, 2024
Software, Radiology, Surgery, General Health, Health, Artificial Intelligence, Medical Devices, Technology, PAE, Interventional radiology, Automation, 2D, ASSIST, Vascular disease, Drainage, Prostatic artery embolization, Allia, OEC, Patient, Artificial intelligence, Society of Interventional Radiology, 3D, Prostate, AI, Quality of life, Artery, Woman, Workflow, GE HealthCare, 3D CT, Embo, E10, Injection, Therapy, BPH, SIR, Medical imaging

GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.
  • The multi-modality showcase will feature innovations focused on precision care delivery for a wide range of vascular diseases and health conditions.
  • As GE HealthCare continues to advance the Allia IGS platform and interventional innovation, Embo ASSIST AI is the latest addition to the company's ASSIST imaging software.
  • “Interventional CT: CT guidance assisted by electromagnetic navigation for percutaneous interventions” with Dr. Francois Cornelis10 on Monday, March 25 from 2:30 - 3:00pm.

Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit

Retrieved on: 
星期四, 三月 14, 2024
Medical Devices, Health, Other Science, General Health, Research, Science, Vascular disease, LSI, Pharmaceutical industry

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that Matt Thompson, President and CEO, will present at the Life Science Intelligence (LSI) USA '24 Emerging Medtech Summit.

Key Points: 
  • Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that Matt Thompson, President and CEO, will present at the Life Science Intelligence (LSI) USA '24 Emerging Medtech Summit.
  • Scheduled for March 20, 2024, at 10:55 am PT on Track 3, Thompson will offer insights into the company's innovative portfolio and its impact on vascular disease treatment.
  • Matt Thompson remarked, "At this pivotal juncture for Endologix, our involvement in the LSI US '24 Emerging Medtech Summit underscores our dedication to spearheading innovation in vascular disease.
  • The summit represents a unique platform for interaction with industry peers and thought leaders, enabling collaborations that are essential for shaping the future of healthcare."

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期三, 三月 6, 2024
CMS, Pi, Growth, Radiology, IDE, State university system, CAD, Buffalo, PMA, MDR, TEL, Medical device regulation, Health, Stroke, CAS, TCAR, EPS, EFS, Thomas Jefferson University, European, Carotid artery stenosis, Myocardial infarction, CE marking, Vascular disease, Thrombectomy, Clinical trial, Medicaid, NPS, CEA, Good Samaritan Hospital, Stenosis, Risk, Blood vessel, Medicare, Death, Stent, Patient, Medicine, NSPR, Pharmaceutical industry

TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 and Recent Developments:
    Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.
  • Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.
  • Financial Results for the Fourth Quarter Ended December 31, 2023
    For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
  • Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022.

Endologix Appoints Mike Mathias as Chief Commercial Officer

Retrieved on: 
星期二, 三月 5, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, TAVR, MD, Strategic planning, MBA, Percutaneous aortic valve replacement, University, Vascular disease, Peripheral artery disease, Organization, Medtronic, EVAR, Endovascular aneurysm repair

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.
  • With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix.
  • Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans.
  • In response to his new role, Mike Mathias shared, "Joining Endologix at such a critical juncture is an honor.

Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study

Retrieved on: 
星期四, 二月 29, 2024
Health, Surgery, Cardiology, Medical Devices, SVS, Woman, TASC, PAD, Moyamoya disease, Society, Vascular disease, SFA, PTAB, Patient, Pharmaceutical industry

The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).

Key Points: 
  • The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).
  • The PTAB1 Post-Market Study evaluates the DETOUR System's performance in patients with very long (TASC D) SFA lesions.
  • The study plans to enroll up to 450 subjects, with a focus on including at least 200 women and also features an imaging sub study.
  • “The initiation of the PTAB1 Post-Market Study represents a pivotal moment in our ongoing commitment to advance the treatment of complex peripheral arterial disease.